The use of IDO inhibitors has been and continues to be investigated for treating GBM to offset the protumor effects of elevated KP activity and for potential synergistic antitumor activity when combined with radiation therapy and/or immune checkpoint inhibitors (11). The gene discussed is NPPA; the disease is glioblastoma.